ArticleBreast cancer research : BCR2020

Comparison of three scoring methods using the FDA-approved 22C3 immunohistochemistry assay to evaluate PD-L1 expression in breast cancer and their association with clinicopathologic factors.

Hua Guo et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.